[HTML][HTML] Serum proteomic profiling of patients with compensated advanced chronic liver disease with and without clinically significant portal hypertension
F Pastrovic, R Novak, I Grgurevic, S Hrkac, G Salai… - Plos one, 2024 - journals.plos.org
Introduction Portal hypertension (PH) drives the progression of liver cirrhosis to
decompensation and death. Hepatic venous pressure gradient (HVPG) measurement is the …
decompensation and death. Hepatic venous pressure gradient (HVPG) measurement is the …
Non‐invasive candidate protein signature predicts hepatic venous pressure gradient reduction in cirrhotic patients after sustained virologic response
SM Richards, F Guo, H Zou, F Nigsch… - Liver …, 2023 - Wiley Online Library
Background and Aims A reduction in hepatic venous pressure gradient (HVPG) is the most
accurate marker for assessing the severity of portal hypertension and the effectiveness of …
accurate marker for assessing the severity of portal hypertension and the effectiveness of …
[HTML][HTML] Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis
Background & Aims In individuals with compensated advanced chronic liver disease
(cACLD), the severity of portal hypertension (PH) determines the risk of decompensation …
(cACLD), the severity of portal hypertension (PH) determines the risk of decompensation …
[HTML][HTML] Future therapy of portal hypertension in liver cirrhosis–a guess
T Sauerbruch, J Trebicka - F1000prime reports, 2014 - ncbi.nlm.nih.gov
In patients with chronic liver disease, portal hypertension is driven by progressive fibrosis
and intrahepatic vasoconstriction. Interruption of the initiating and perpetuating etiology …
and intrahepatic vasoconstriction. Interruption of the initiating and perpetuating etiology …
[HTML][HTML] Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD
Abstract Background & Aims Metabolic dysfunction-associated steatotic liver disease
(MASLD) is a leading cause of advanced chronic liver disease (ACLD). Portal hypertension …
(MASLD) is a leading cause of advanced chronic liver disease (ACLD). Portal hypertension …
Metabolomics reveals altered metabolites in cirrhotic patients with severe portal hypertension in Tibetan population
Y Ye, C Xia, H Hu, S Tang, H Huan - Frontiers in Medicine, 2024 - frontiersin.org
Background Portal hypertension (PHT) presents a challenging issue of liver cirrhosis. This
study aims to identify novel biomarkers for severe PHT (SPHT) and explore the …
study aims to identify novel biomarkers for severe PHT (SPHT) and explore the …
[HTML][HTML] Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality
Background & Aims Distinct prognostic stages of advanced chronic liver disease (ACLD) are
defined by severity of portal hypertension (PH) and the presence/absence of clinical …
defined by severity of portal hypertension (PH) and the presence/absence of clinical …
Metabolomics as a diagnostic tool for idiopathic non‐cirrhotic portal hypertension
S Seijo, JJ Lozano, C Alonso, R Miquel… - Liver …, 2016 - Wiley Online Library
Background Idiopathic non‐cirrhotic portal hypertension (INCPH) is a rare life‐threatening
liver disease that lacks a specific diagnostic test being frequently misdiagnosed as …
liver disease that lacks a specific diagnostic test being frequently misdiagnosed as …
Metabolomics discloses potential biomarkers for the noninvasive diagnosis of idiopathic portal hypertension
S Seijo, JJ Lozano, C Alonso, E Reverter… - Official journal of the …, 2013 - journals.lww.com
OBJECTIVES: Idiopathic portal hypertension (IPH) is a rare cause of portal hypertension that
lacks a specific diagnostic test. Requiring ruling-out other causes of portal hypertension it is …
lacks a specific diagnostic test. Requiring ruling-out other causes of portal hypertension it is …
[HTML][HTML] Noninvasive imaging assessment of portal hypertension: where are we now and where does the future lie?
S Wan, X Liu, H Jiang, Z Teng… - Expert Review of Molecular …, 2021 - Taylor & Francis
The comprehensive management of chronic liver disease and subsequent portal
hypertension (PH) remains a challenge in clinical treatment. The consequences of PH are …
hypertension (PH) remains a challenge in clinical treatment. The consequences of PH are …